Targeting DDX3X impairs the CSC population in cisplatin-resistant cells via decreased expression of FOXM1 and NANOG [86], which are important for self-renewal properties and drug resistance in cancers that are upregulated by the m6A demethylase ALKBH5 [43, 153–156]. The gene discussed is DDX3X; the disease is cancer.